MannKind Corp. took one squarely on the chin Thursday as the market responded to breaking news late Wednesday that the FDA had issued a second complete response letter for inhaled insulin candidate Afrezza (insulin human [rDNA origin] to treat adults with Type I and Type II diabetes. (See BioWorld Today, Jan. 20, 2011.)